Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2

Parkinsonism and Related Disorders

Volumn 20, Issue 10, 2014, Pages 1097-1100

  Estanga, A ^a,d   Rodriguez Oroz, M C ^a,b,c   Ruiz Martinez, J ^a,b   Barandiaran, M ^a,b   Gorostidi, A ^a   Bergareche, A ^a,b   Mondragon, E ^a,b   Lopez de Munain, A ^a,b,d   Marti Masso, J F ^a,b,d  

^a BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^b HOSPITAL DONOSTIA   (Spain)

^c BASQUE FOUNDATION FOR SCIENCE   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Cognitive impairment; LRRK2; Mood; Parkinson's disease; R1441G mutation

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; LEVODOPA; ARGININE; GLYCINE; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; ATTENTION; BECK DEPRESSION INVENTORY; BRAIN FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DEPRESSION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LRRK2 GENE; MALE; MEMORY; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; PREVALENCE; UNIFIED PARKINSON DISEASE RATING SCALE; VERY ELDERLY; CASE CONTROL STUDY; COGNITION DISORDERS; COMPLICATION; GENETICS; MUTATION; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; AGED, 80 AND OVER; ARGININE; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; GLYCINE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; SEVERITY OF ILLNESS INDEX;

EID: 84908145945     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.07.005     Document Type: Article

References (17)

1. Gorostidi A., Ruiz-Martinez J., Lopez de M.A., Alzualde A., Marti Masso J.F. LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity. Neurogenetics 2009 Apr, 10(2):157-159.
2. Mata I.F., Ross O.A., Kachergus J., Huerta C., Ribacoba R., Moris G., et al. LRRK2 mutations are a common cause of Parkinson's disease in Spain. Eur J Neurol 2006, 13:391-394.
3. Gonzalez-Fernandez M.C., Lezcano E., Ross O.A., Gómez-Esteban J.C., Gomez-Busto F., Velasco F. LRRK2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism Relat Disord 2007, 13:509-515.
4. Gaig C., Ezquerra M., Martí M.J., Muñoz E., Vallderiola F., Tolosa E. LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance. Arch Neurol 2006, 63:377-382.
5. Paisan-Ruiz C., Saenz A., Lopez de M.A., Marti I., Martinez G.A., Marti-Masso J.F., et al. Familial Parkinson's disease: clinical and genetic analysis of four Basque families. Ann Neurol 2005 Mar, 57(3):365-372.
6. Emre M., Aarsland D., Brown R., Burn D.J., Duyckaerts C., Mizuno Y., et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007 Sep 15, 22(12):1689-1707.
7. Litvan I., Goldman J.G., Troster A.I., Schmand B.A., Weintraub D., Petersen R.C., et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: movement Disorder Society Task Force guidelines. Mov Disord 2012 Mar, 27(3):349-356.
8. Healy D.G., Falchi M., O'Sullivan S.S., Bonifati V., Durr A., Bressman S., et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008 Jul, 7(7):583-590.
9. Goldwurm S., Zini M., Di F.A., De G.D., Siri C., Simons E.J., et al. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord 2006 Oct, 12(7):410-419.
10. Belarbi S., Hecham N., Lesage S., Kediha M.I., Smail N., Benhassine T., et al. LRRK2 G2019S mutation in Parkinson's disease: a neuropsychological and neuropsychiatric study in a large Algerian cohort. Parkinsonism Relat Disord 2010 Dec, 16(10):676-679.
11. Shanker V., Groves M., Heiman G., Palmese C., Saunders-Pullman R., Ozelius L., et al. Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease. Mov Disord 2011 Aug 15, 26(10):1875-1880.
12. Litvan I., Aarsland D., Adler C.H., Goldman J.G., Kulisevsky J., Mollenhauer B., et al. MDS task force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord 2011 Aug 15, 26(10):1814-1824.
13. Marras C., Armstrong M.J., Meaney C.A., Fox S., Rothberg B., Reginold W., et al. Measuring mild cognitive impairment in patients with Parkinson's disease. Mov Disord 2013 May, 28(5):626-633. 10.1002/mds.25426.
14. Aarsland D., Bronnick K., Williams-Gray C., Weintraub D., Marder K., Kulisevsky J., et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010 Sep 21, 75(12):1062-1069.
15. Berg D., Schweitzer K.J., Leitner P., Zimprich A., Lichtner P., Belcredi P., et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain 2005 Dec, 128(Pt 12):3000-3011.
16. Reijnders J.S., Ehrt U., Weber W.E., Aarsland D., Leentjens A.F. Asystematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008 Jan 30, 23(2):183-189.
17. Riedel O., Klotsche J., Spottke A., Deuschl G., Forstl H., Henn F., et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease. JNeurol 2010 Jul, 257(7):1073-1082.